164 related articles for article (PubMed ID: 34357460)
1. T1 glottic laryngeal cancer: the role of routine follow-up visits in detecting local recurrence.
Pakkanen P; Ilmarinen T; Halme E; Irjala H; Koivunen P; Pukkila M; Ventelä S; Hagström J; Aaltonen LM
Eur Arch Otorhinolaryngol; 2021 Dec; 278(12):4863-4869. PubMed ID: 34357460
[TBL] [Abstract][Full Text] [Related]
2. Management of T3N1 glottic carcinoma: therapeutic outcomes.
Spector JG; Sessions DG; Lenox J; Simpson J
Laryngoscope; 2006 Jan; 116(1):106-10. PubMed ID: 16481820
[TBL] [Abstract][Full Text] [Related]
3. Value of routine follow-up for recurrence detection after treatment with curative intent for laryngeal squamous cell carcinoma.
van de Weerd C; Geurts SME; Vercoulen RJMT; van Veggel IHF; Brands MT; Marres HAM; Hermens RPMG; van Tol-Geerdink JJ; Kaanders JHAM; Takes RP
Eur J Surg Oncol; 2024 Jan; 50(1):107304. PubMed ID: 38043360
[TBL] [Abstract][Full Text] [Related]
4. Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas.
Wachters JE; Kop E; Slagter-Menkema L; Mastik M; van der Wal JE; van der Vegt B; de Bock GH; van der Laan BFAM; Schuuring E
Laryngoscope; 2020 Dec; 130(12):2825-2832. PubMed ID: 32065407
[TBL] [Abstract][Full Text] [Related]
5. The role of protein p16(INK4a) in glottic laryngeal squamous cell carcinoma.
Kalfert D; Celakovsky P; Laco J; Ludvikova M
Pathol Oncol Res; 2014 Oct; 20(4):909-15. PubMed ID: 24760498
[TBL] [Abstract][Full Text] [Related]
6. Impact of stage, management and recurrence on survival rates in laryngeal cancer.
Brandstorp-Boesen J; Sørum Falk R; Boysen M; Brøndbo K
PLoS One; 2017; 12(7):e0179371. PubMed ID: 28708883
[TBL] [Abstract][Full Text] [Related]
7. Management of T3N0M0 glottic carcinoma: therapeutic outcomes.
Sessions DG; Lenox J; Spector GJ; Newland D; Simpson J; Haughey BH; Chao KS
Laryngoscope; 2002 Jul; 112(7 Pt 1):1281-8. PubMed ID: 12169914
[TBL] [Abstract][Full Text] [Related]
8. Oncological outcomes of early glottic carcinoma treated with transoral robotic surgery.
Kayhan FT; Koc AK; Erdim I
Auris Nasus Larynx; 2019 Apr; 46(2):285-293. PubMed ID: 30217617
[TBL] [Abstract][Full Text] [Related]
9. Importance of anterior commissure in recurrence of early glottic cancer after laser endoscopic resection.
Chone CT; Yonehara E; Martins JE; Altemani A; Crespo AN
Arch Otolaryngol Head Neck Surg; 2007 Sep; 133(9):882-7. PubMed ID: 17875854
[TBL] [Abstract][Full Text] [Related]
10. Factors leading to the use of alternate treatment modalities following transoral laser excision of T1 and T2 glottic squamous cell carcinoma.
Pham TA; De Freitas R; Sigston E; Vallance N
ANZ J Surg; 2012 Oct; 82(10):720-3. PubMed ID: 22901105
[TBL] [Abstract][Full Text] [Related]
11. Stage I (T1 N0 M0) squamous cell carcinoma of the laryngeal glottis: therapeutic results and voice preservation.
Spector JG; Sessions DG; Chao KS; Haughey BH; Hanson JM; Simpson JR; Perez CA
Head Neck; 1999 Dec; 21(8):707-17. PubMed ID: 10562683
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated FADD is not prognostic for local control in T1-T2 supraglottic laryngeal carcinoma treated with radiotherapy.
Wachters JE; Schrijvers ML; Slagter-Menkema L; Mastik M; Langendijk JA; de Bock GH; Roodenburg JL; van der Laan BFAM; van der Wal JE; Schuuring E
Laryngoscope; 2017 Sep; 127(9):E301-E307. PubMed ID: 28304089
[TBL] [Abstract][Full Text] [Related]
13. Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability.
Held T; Franke H; Lang K; Eichkorn T; Regnery S; Weusthof K; Bauer L; Plath K; Dyckhoff G; Plinkert PK; Harrabi SB; Herfarth K; Debus J; Adeberg S
Radiat Oncol; 2022 Dec; 17(1):199. PubMed ID: 36471398
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy Versus Cordectomy in the Management of Early Glottic Cancer.
Chung SY; Kim KH; Keum KC; Koh YW; Kim SH; Choi EC; Lee CG
Cancer Res Treat; 2018 Jan; 50(1):156-163. PubMed ID: 28301924
[TBL] [Abstract][Full Text] [Related]
15. Exclusive radiotherapy for stage T1-T2N0M0 lanryngeal cancer: retrospective study of 59 patients at CFB and CHU de Caen.
Cuny F; Géry B; Florescu C; Clarisse B; Blanchard D; Rame JP; Babin E; De Raucourt D
Eur Ann Otorhinolaryngol Head Neck Dis; 2013 Nov; 130(5):251-6. PubMed ID: 23759281
[TBL] [Abstract][Full Text] [Related]
16. Management of stage IV glottic carcinoma: therapeutic outcomes.
Spector GJ; Sessions DG; Lenox J; Newland D; Simpson J; Haughey BH
Laryngoscope; 2004 Aug; 114(8):1438-46. PubMed ID: 15280724
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results.
Laccourreye O; Brasnu D; Bassot V; Ménard M; Khayat D; Laccourreye H
J Clin Oncol; 1996 Aug; 14(8):2331-6. PubMed ID: 8708725
[TBL] [Abstract][Full Text] [Related]
18. Does waiting time for radiotherapy affect local control of T1N0M0 glottic laryngeal carcinoma?
Brouha XD; Op De Coul B; Terhaard CH; Hordijk GJ
Clin Otolaryngol Allied Sci; 2000 Jun; 25(3):215-8. PubMed ID: 10944052
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors and treatment outcome of laryngeal carcinoma recurrence.
Haapaniemi A; Väisänen J; Atula T; Alho OP; Mäkitie A; Koivunen P
Head Neck; 2017 Mar; 39(3):555-563. PubMed ID: 27902867
[TBL] [Abstract][Full Text] [Related]
20. Treatment and Survival Trends in Glottic Carcinoma in Situ and Stage I Cancer From 1988 to 2012.
Khaja SF; Hoffman HT; Pagedar NA
Ann Otol Rhinol Laryngol; 2016 Apr; 125(4):311-6. PubMed ID: 26481178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
